Sumitomo Pharma Co., Ltd.
Stock Price Chart
2026/08/05 UpdatedPrice Trend
2026/08/05 UpdatedPrice & Trading Details
2026/08/05 UpdatedPRICE
TRADING
Analyst Recommendations 6 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/07/30 | ¥19.13 | ¥39.02 | +104.0% |
| 2026/05/13 | ¥-15.24 | ¥-2.04 | +86.6% |
| 2026/01/30 | ¥-0.87 | ¥22.19 | +2,650.6% |
| 2025/10/30 | ¥18.07 | ¥220.63 | +1,120.8% |
Shareholder Composition
Updated 2026/08/01Top Mutual Funds / ETFs
Updated 2026/08/01Major Holders
Updated 2026/08/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
2.7M | +10.61% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.7M | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
1.6M | +2.37% | |
|
T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Intl Discovery Fd.
|
1.5M | +1.00% | |
|
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.
|
1.4M | -27.37% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
955.8K | -0.25% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Legato Capital Management LLC
|
41.1K | +52.50% |
Dividend History
Updated 2026/08/02| Year | Dividend | Change |
|---|---|---|
| 2023 | ¥7 | -75.0% |
| 2022 | ¥28 | 0.0% |
| 2021 | ¥28 | 0.0% |
| 2020 | ¥28 | -20.0% |
| 2019 | ¥35 | - |
Financial Performance
2026/08/02 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥560,035M | ¥555,544M | ¥314,558M | ¥398,832M |
| Gross Profit | ¥402,908M | ¥376,625M | ¥187,981M | ¥245,395M |
| Operating Income | ¥60,234M | -¥76,979M | -¥354,836M | ¥29,709M |
| Pretax Income | ¥86,011M | -¥44,761M | -¥318,837M | ¥31,111M |
| Net Income | ¥56,413M | -¥74,512M | -¥314,969M | ¥23,634M |
| EPS | ¥141.99 | -¥187.55 | -¥792.79 | ¥59.49 |
| Operating Margin | 10.76% | -13.86% | -112.80% | 7.45% |
| Balance Sheet | ||||
| Total Assets | ¥1,308,007M | ¥1,134,742M | ¥907,506M | ¥742,604M |
| Total Equity | ¥607,888M | ¥406,749M | ¥156,063M | ¥169,479M |
| Total Liabilities | ¥700,119M | ¥727,993M | ¥751,443M | ¥573,125M |
| Cash | ¥202,984M | ¥143,478M | ¥29,047M | ¥23,116M |
| Interest-bearing Debt | ¥269,048M | ¥334,716M | ¥418,884M | ¥305,422M |
| Equity Ratio | 46.47% | 35.85% | 17.20% | 22.82% |
| D/E Ratio | 0.44 | 0.82 | 2.68 | 1.80 |
| Cash Flow | ||||
| Operating CF | ¥31,239M | ¥11,937M | -¥241,893M | ¥16,500M |
| Investing CF | -¥18,278M | ¥52,419M | ¥33,036M | ¥99,754M |
| Financing CF | -¥21,426M | -¥146,817M | ¥77,851M | -¥108,836M |
| Free CF | ¥17,745M | -¥805M | -¥257,623M | ¥3,470M |
| Efficiency | ||||
| ROE | 9.28% | -18.32% | -201.82% | 13.95% |
| ROA | 4.31% | -6.57% | -34.71% | 3.18% |
Latest IR Information
-
Report about the Company
This letter serves to inform the consent/verification matters related to external reporting on Sumitomo Pharma Co., Ltd. The content does not include the contents or conclusions of the public report or disclosure of financial indicators.
Read more -
【Sumitomo Pharma】Core Company of Pharmaceutical Business | June 25, 2026
Sumitomo Pharma conducts its pharmaceutical business under the control of its parent company, Sumitomo Chemical, and discloses information regarding sales and business strategies for the fiscal year ending March 2026.
Read more -
Sumitomo Pharma's Non-Implementation of Share Issue to Third Parties｜May 22, 2026
Sumitomo Pharma announced that it has decided not to proceed with the planned third-party allotment of shares at the Board of Directors meeting on April 8, 2026, and that the 7,695,600 shares scheduled for issuance will not be issued.
Read more -
【Sumitomo Pharma】Fiscal Year 2025 Financial Results | Sales of 533 billion yen (+19.1% YoY)
Sumitomo Pharma achieved sales of 533 billion yen (up 19.1% YoY) in fiscal year 2025, with operating profit significantly increased to approximately 107 billion yen. Overseas sales ratio also expanded to 81.6%, strengthening the future growth foundation.
Read more -
Financial Results Briefing for FY2025 (March 2026)
Sales revenue for FY2025 was ¥453.3 billion (up 13.7% YoY), operating income was ¥107.3 billion (up 272.6% YoY), and net income attributable to owners of the parent was ¥106.9 billion (up 352.2% YoY).
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥2,086
Rating Score: 2.43 (Based on 6 analysts)
※1=Strong Buy, 5=Strong Sell
Sumitomo Pharma says no evidence of misstatements after Gotham City Research report - Bitget ↗
Company Information
About
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
